Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 10/20 | 0.47 |
| ▸ | SRC | P12931 | 7/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.47 |
| ▸ | SYK | P43405 | 6/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.46 |
| ▸ | HCK | P08631 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19732050 | 0.92 | SRC (0.50) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL19731946 | 0.91 | MAPK14 (0.41) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL14656109 | 0.91 | MAPK14 (0.58) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL19732102 | 0.89 | GSK3A (0.52) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL19732076 | 0.88 | GSK3A (0.51) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL19388896 | 0.87 | MAPK12 (0.45) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL19732037 | 0.87 | MAPK12 (0.56) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL19731945 | 0.85 | GSK3A (0.59) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL14656290 | 0.84 | MAPK14 (0.63) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL14656479 | 0.83 | MAPK14 (0.52) | GSK3ASRCMAPK14SYKMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170362208-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362208-A1 | NOVEL COMPOUNDS | ARG1, IL1B, LTB4R | GSK3A 3153/4885SRC 3928/4885MAPK14 4207/4885 |
| US-10000471-B2 | Pyrazole P38 map kinase inhibitors | MAPK1, MAP3K1, MAPK3 | GSK3A 990/4885SRC 872/4885MAPK14 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.